Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Scientific Reports|October 21, 2021
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Juan M Alonso-Dominguez, Eva Barragán, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Cancer|June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Frontiers in Immunology|March 12, 2024
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphomaLourdes Hontecillas-Prieto, Daniel J García-Domínguez, Natalia Palazón-Carrión, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker SubanalysisNatalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Hematological Oncology|January 9, 2026
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA RegistryEsther Prados de la Torre, Josefina Serrano, Eva Barragán, et al.
Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.
Pageof 9